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The role of endoplasmic reticulum (ER) stress is a rapidly emerging ﬁeld of interest in the pathogenesis of metabolic diseases.
Recent studies have shown that chronic activation of ER stress is closely linked to dysregulation of lipid metabolism in several
metabolically important cells including hepatocytes, macrophages, β-cells, and adipocytes. Adipocytes are one of the major
cell types involved in the pathogenesis of the metabolic syndrome. Recent advances in dissecting the cellular and molecular
mechanisms involved in the regulation of adipogenesis and lipid metabolism indicate that activation of ER stress plays a central
role in regulating adipocyte function. In this paper, we discuss the current understanding of the potential role of ER stress in
lipid metabolism in adipocytes. In addition, we touch upon the interaction of ER stress and autophagy as well as inﬂammation.
Inhibition of ER stress has the potential of decreasing the pathology in adipose tissue that is seen with energy overbalance.
1.Introduction
In the last two decades, the complexity of adipose tissue
has ﬁnally become apparent. Investigations surrounding the
biological impact of obesity, insulin resistance, and the met-
abolic syndrome have surged, resulting in a more intricate
understanding of “fat.” Adipose tissue (AT) is not only highly
specialized to store long-term energy, but is also a central
endocrine organ. Therefore, AT is inherently involved in the
interplay of inﬂammatory cascades and energy metabolism,
which are important players in metabolic disorders. Even
more, sick fat, or adiposopathy, has now been coined an
independent endocrine disease [1].
Adiposopathy can occur environmentally through over-
nutrition. Adipocytes store extra energy in the form of tri-
glycerides (TG) inside cytosolic organelles (lipid droplets,
or LD). When there is a continuous need to store TGs,
adipocytes must expand in size while continuously being
stressed to synthesize more proteins for LD formation.
There is an inherent threshold at which adipocytes be-
come too stressed, secrete multiple cytokines, and can no
longer expand. The cytokines released activate resident
macrophages and call in circulating macrophages, which
begin to attempt to engulf these cells, forming the signature
“crownlike structures” found in obese tissue [2].
During this cascade, increased cytokines can increase
adipocyte lipolysis. Increased lipolysis leads to an increase of
circulating free fatty acids (FFA) that are deposited in muscle
andliver(“lipiddumping”)andresultsinadecreasedinsulin
sensitivity in these tissues (reviewed in [3]). Particularly,
FFA from visceral AT is directly deposited into the portal
vein, increasing the risk of fatty liver disease. This may be
the underlying basis of current clinical understanding that
increased visceral fat is a high-risk factor for cardiovascular
disease [4, 5].
An increase in FFA release is not only induced by an
inﬂammatory state in AT, but also cellular insulin insensi-
tivity. For this reason, most literature focusing on adipocyte
dysregulation in metabolic disease concentrates on the
nutrient sensing pathways. However, another important
pathway involved in adipocyte pathology is the induction of
endoplasmic reticulum (ER) stress. In the past, overstimu-
lation of ER stress has been linked to diseases of genetics
and aging (reviewed in [6]), but may in fact be involved in
more environmentally induced diseases as well. This paper2 Biochemistry Research International
discusses the recent understanding regarding the role of ER
stress in regulating lipid metabolism in adipocytes and the
clinical consequence therein.
2. ERStress inthe Adipocyte
Numerous cellular pathways can be altered in times of stress,
leading to cellular aberrations and dysfunction. However,
in the realm of overnutrition, ER stress is arguably the
most common and important [7–10]. The ER is central
for protein folding, secretions (e.g., cytokines), calcium
homeostasis, and lipid synthesis. In the adipocyte, the ER
is directly involved with LD formations and maintenance of
lipid homeostasis.
Inducing ER stress is relatively eﬀortless via depletion
of ER calcium stores, changes in ER lipid membrane com-
position, reactive oxygen species (ROS), or accumulation of
misfolded and/or unfolded proteins. When triggered, the ER
signals to the cell through the unfolded protein response
(UPR) to aid in increased production of proteins needed for
protein folding, while decreasing transcription and increas-
ing degradation of other nonessential proteins. If the UPR
is unable to return the ER to homeostatic conditions, it will
trigger apoptosis.
A central component of the UPR is an ER chaperone
protein, BiP/GRP78. In homeostatic conditions, BiP/GRP78
is bound to three ER membrane resident proteins. An insult
that alters ATP in the lumen decreases calcium, or increases a
demand for protein folding causes GRP78 to unbind. These
three proteins, ER transmembrane kinase/endoribonuclease
IRE1,double-strandedRNA-activatedproteinkinase-likeER
kinase (PERK), and activating transcription factor 6 (ATF-
6), trigger a cascade upon their release, which ultimately
leadstotheactivationoftranscriptionfactorsthatupregulate
protein chaperones, proteasome components, and with
continuous activation, turns on GADD-153/CHOP (C/EBP
homologous protein), a major transcriptional factor respon-
sible for ER-stress-induced apoptosis.
2.1. IRE1. Upon release from GRP78, IRE1 transautophos-
phorylates, activating its RNase activity. The activated IRE1
speciﬁcally acts on its downstream target X-box-binding
pr otein1(XBP1)andremovesa26basepairintronsequence
of XBP1 resulting in the formation of spliced XBP1 (XBP1s).
TherearemultipletargetsofXBP1s,suchasERpr oteinchap-
erones and proteins involved in ER-associated degradation
(ERAD) [11–13]. However, beyond the traditional genes it
activates, the biological function of XBP1s has now been
shown to be more diverse.
In fact, XBP1’s ability to induce many ER proteins, and
increaseexpansionoftheroughER[14]hasdemonstratedits
necessity in ER biogenesis. Speciﬁc and elaborate knockout
models have demonstrated this further; when the ER was
poorly developed, secretory cells subsequently failed to
function [15, 16]. Sriburi et al. have found that overex-
pression of XBP1s in preadipocytes induces upregulation of
the rate-limiting enzyme in phosphatidylcholine synthesis
(CTP: phosphocholine cytidylyltransferase or CCT) [14,
17]. As this is the major phospholipid found in the ER
membrane, it follows that XBP1 increases ER biogenesis by
bothstimulationofERproteinsandmembranecomponents.
This activity of XBP1 is most likely not cell speciﬁc, due
to the already described centrality of this transcription factor
in secretory cell types and hepatocytes. What is of interest in
adipocytes, however, is the close interplay of ER biogenesis
and LD formations. LDs, as mentioned previously, are a
central organelle in adipocytes, though they also are found
to a much lesser extent in other cells such as hepatocytes
and macrophages. LDs are known to contain a core of tria-
cylglycerols and cholesterol, but the multiple proteins found
in their phospholipid monolayer are only beginning to be
understood [18]. Although it is already known that the ER
assembles and processes the lipids and proteins needed for
LD formation, it is not fully known how they are transferred.
The formation of a na¨ ıve LD is hypothesized to occur when
neutral lipids accumulate at the ER membrane and then
bud oﬀ. However, others propose LDs form as a bicelle or
vesicular budding. In addition, the ER may in fact remain
linked to LDs, allowing free exchange of proteins [19, 20].
Beyond the debate on whether these two organelles are
physically linked, there is no dispute on the centrality of
CCT. When CCT is limited, LDs begin to fuse due to less
phosphatidylcholine on their surface [21]. Even more, when
onegeneofCCTwasknockeddown60%indrosophila,there
was a signiﬁcant increase of triacylglycerol content [21]. This
may be a compensation in which diacylglycerols normally
utilized in the CCT pathway are now channeled to neutral
lipids in the LDs. Nonetheless, the main end is larger and
denser LDs with less active CCT.
The link between CCT, LDs, and the UPR is most likely
the foundation of the essential nature of the IRE1-XBP1
pathway in adipogenesis. XBP1-shRNA-treated preadipo-
cytes fail to diﬀerentiate, and only transduction of the XBP1s
rescued cells [22]. In vivo mouse models are more diﬃcult
to handle, as the full XBP1 knockout die in utero [15]. To
circumvent this, one group has placed a liver-speciﬁc XBP1
gene into this model, but even these mice die during the
neonatal starvation period [16]. These mice are smaller with
a negligible white adipose mass, even compared to their
heterozygous counterparts.
The mechanism underlying XBP1’s signiﬁcant role may
be due to the upregulation of CCAAT/enhancer-binding
protein-α (C/EBPα)[ 22]. CCAAT/enhancer-binding pro-
teins are essential transcription factors in adipogenesis, with
β and δ being major players in early diﬀerentiation and α
essential in mid- to late diﬀerentiation. Sha et al. found that
XBP1s upregulates C/EBPα, and C/EBPβ increases transcrip-
tion of XBP1 [22]. Therefore, XBP1 is integral in the loop of
transcriptional activation of adipocyte diﬀerentiation as well
as the functional maturation of LD formation.
2.2. PERK. The PERK-eIF2α pathway is another UPR leg
involved in adipogenesis. When released, PERK transauto-
phosphorylates leading to activation of its kinase domain.
The major result of this is phosphorylation of eukaryotic
translation initiation factor 2α (eIF2α). In the phospho-
rylated state, this essential component of the translational
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but at the same time increasing the translation of mRNAs
which contain internal ribosome entry sites, such as ATF-4,
BiP/GRP78, and SREBP-1 [23–25].
Activating transcription factor (ATF)-4 is a well-studied
protein involved in the UPR (reviewed in [26]). This tran-
scription factor is heavily involved in increasing amino acid
metabolism and protein transport [27, 28]. Importantly,
ATF-4 also upregulates stress-related transcription factors
ATF-3 and CHOP. CHOP is a central transcription factor
involved in cellular perturbations, including inhibition of
adipocyte diﬀerentiation [29–31], and ultimately inducing
apoptosis. However, there is still necessity of balance as
although high induction of ATF-4 will lead to CHOP activa-
tion, complete absence will aﬀect AT lipogenesis [32]. More
studies are needed to fully understand the role of ATF-4 in
lipogenesis in adipocytes.
In contrast, more is understood about SREBPs( s t e r o l
regulatory element-binding proteins). SREBPs are additional
transcription factors found in the ER membrane. There are
three isoforms- SREBP-1a, -1c, and -2. SREBP-1c is involved
in fatty acid synthesis and lipogenesis, -2 in cholesterol
synthesis,and-1ainbothpathways.TheSREBPsareretained
in the ER via insulin-induced gene (Insig) binding to
SREBP-cleavage-activating-protein-(SCAP-) bound SREBP.
At times of sensed decreases in cholesterol or fatty acids,
SCAP-SREBP dissociates from Insig and relocates to the
Golgi where SREBP is cleaved by two site proteases (S1P
and S2P). The mature form of SREBP further translocates
to the nucleus, activating genes involved in cholesterol
and lipid metabolism, such as 3-hydroxy-3-methylgutaryl-
CoA (HMG-CoA) synthase, HMG-CoA reductase, squalene
synthase, acetyl-CoA carboxylase (ACC), and fatty acid
synthase (FAS). Therefore, disruption of ER homeostasis not
only alters protein production, but also aﬀects cholesterol
and fatty acid synthesis.
Normally, SREBPs are released when there is a sense of
depletion of cholesterol or lipids in the ER membrane. How-
ever, SREBP1 processing is also regulated through PERK-
eIF2α. In fact, knockout of PERK substantially decreases
active SREBP1 in mammary glands [33]. This is most likely
a result from the recent ﬁnding that SREBP1 contains an
internal ribosome entry site [23]. Therefore, activation of ER
stress will redundantly lead to active SREBP1 through both
upregulation of translation and release of protein from the
membrane.
In adipocytes of the SREBPs isoform, -1c is the most
highlyexpressed.SREBP1cisanessentialtranscriptionfactor
during adipogenesis (and thus has a dual name of adipocyte
determination and diﬀerentiation 1/ADD1). Likewise, the
PERK pathway has also been found to be important during
diﬀerentiation of adipocytes in vitro [33]. Overexpression
of ADD1/SREBP1c leads to an increase of LD formation in
preadipocytes, while conditional overexpression in mouse
AT inhibits normal mass growth [34]. In addition, SREBP1c
has been shown to directly activate C/EBPβ [35], further
supporting its role in adipogenesis. The contradictory results
demonstrated with the above mouse models may demon-
strate the balance needed by all transcription factors for
functional and normal AT.
2.3. ATF-6. There are two genes encoding ATF-6, α,a n d
β.T h eα isoform is a strong transcriptional activator [36],
and the form classically studied during UPR activation.
When ATF-6 is released from GRP78, it is translocated to
the Golgi via a localization signal that was hidden when
in the bound form. In the Golgi, ATF-6 is cleaved by the
same proteases that process SREBPs, releasing the active
cytoplasmic domain, which is a transcription factor. Here,
ATF6α heterodimerizes with XBP1 and upregulates genes
with the ER stress response element (ERSE) in their promot-
ers, including GRP78 [37] and other ER chaperone proteins,
CHOP, and even XBP1 (reviewed in [38]).
In the realm of UPR activation altering lipid metabolism
in adipocytes, not much has been noted in the literature
concerning ATF6. Knockout mouse models of either ATF6α
or β do not show any striking physiological changes, but
have allowed for the clariﬁcation that ATF6α is the more
essential isoform for the ER stress pathway [39], though β
is also involved [36]. Some work has recently demonstrated
that ATF6 activation plays a role in the liver to control lipid
deposition [40, 41] through inhibition of SREBP-2 [42].
What is of more importance in the adipocyte is the direct
function of ATF6 to upregulate XBP1, described above as
central in adipogenesis.
ATF6α heterodimerizes with XBP1s in the nucleus to
activate genes downstream of UPR activation. However, it
is currently not shown if this relationship is also required
forupregulationofC/EBPα,o rCCTacti vity .M o r ein v estiga-
tions are needed to completely elucidate the direct function
of ATF6 in adipocyte lipid metabolism.
3. Autophagy, the UPR, andLipid
Metabolism Dysregulation
Autophagy is a self-protective cellular pathway activated by
multiple stimuli including viral infection, perceived star-
vation, organelle dysfunction, and ER stress (discussed
below). However, just as in the case of UPR, autophagy has
the ability to increase cellular damage or cell death when
overstimulated. The multifaceted autophagic pathway is
continuously being studied, as is the capacity of this process
to help regulate metabolism in mammalian cells. In the past
few years, an expanding area of research has unfurled around
autophagy and lipid metabolism regulation. In hepatocytes,
autophagosomes aid in the control of lipid accumulations
by delivering LDs to lysosomes [43]. Similarly, in neurons
altered autophagy leads to lipid accumulation [44]. Due to
its obvious role in lipid metabolism, Singh and colleagues
have now coined this leg of autophagy as lipophagy, in which
lipid droplets are degraded through autophagy rather than
lipolysis [45].
Further, components of the autophagosome may be
necessary for lipid droplet formations [46]. This link was
found through the microtubule-associated protein 1A/1B
light chain 3 (LC3), an essential protein in the autophagy
pathway. At induction of autophagy, a double membrane
sequesters components of the cytoplasm through the coor-
dination of multiple proteins and membrane expansion.
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otherautophagic-speciﬁcproteinsbycleavageandlipidation,
converting it to membrane-bound LC3-II. Shibata et al. have
found that LC3-II does not only colocalize to autophago-
somes (the speciﬁc autophagy sequestering vacuoles), but
also to LDs in hepatocytes and cardiac myocytes [46]. This
same group has also demonstrated that LC3 colocalizes
to LDs in diﬀerentiating adipocytes by using LC3-siRNA
[47]. The siRNA of LC3 drastically decreased the ability of
adipogenesis [47]. LC3-II has been shown to have tethering
capacity to help the fusion of autophagosomes to lysosomes
[48]. Therefore, there is a hypothesis that LC3-II is acting to
bring LDs into the autophagosome pathway for downstream
lipid breakdown [43, 49]. This would provide another
pathway of lipid ﬂux beyond lipases acting directly on the
LD.
Knockout models have demonstrated how essential
autophagy is in adipogenesis. Baerga et al. were able to
establish this by ﬁrst showing the signiﬁcant increase of
autophagosome formations during induction of adipogene-
sis,followedbytheinhibitionofdiﬀerentiationinaknockout
atg5 mouse model [50]. Atg5 encodes a protein that is
required similarly to LC3 for the maturation of the pre-
autophagosome. Using this model, Baerga et al. saw both
in vitro and in vivo that inhibition of autophagy restrained
maturationofpreadipocytes,resultinginamarkedreduction
of WAT in neonatal mice (this mouse model is not able to
survive the neonatal starvation period). Of most interest,
in the knockout mouse embryonic ﬁbroblasts induced
to diﬀerentiate, cells that began to mature died through
apoptosis, while those in the same culture that did not
begintodiﬀerentiateremainedalive.Thisstudywasfollowed
by another with adipose-speciﬁc deletion of atg7 [51],
the gene encoding an essential protein upstream of Atg5.
Interestingly, WAT tissue of this knockout model was more
characteristic of BAT in both morphology (smaller cells
and LDs) and enzyme levels. The importance of Atg7 in
adipogenesis was conﬁrmed by Singh et al. who knocked
down the same gene, but used slightly diﬀerent cell lines
and mouse model [43]. However, both groups came upon
the same ﬁnding that the autophagic pathway is essential in
adipogenesis.
The trigger of autophagy activation during adipogenesis
is currently not known. However, PPARγ, an essential
transcription factor of adipogenesis, may be involved. In one
cancercellline,itwasfoundthatPPARγ agonistscanactivate
the autophagy pathway [52]. Yet, there is another study that
contradicts these ﬁndings [53], and such investigations have
not yet been repeated in an adipocyte model. Nonetheless,
the summation of above experiments does demonstrate that
autophagy is essential in adipogenesis, and without, may
cause a transdiﬀerentiation of WAT to BAT. On the other
hand, a decrease of autophagy in the liver leads to lipid
overload in hepatocytes. Intuitively, the diﬀerence lies in the
biology of the two cell types, where adipocytes are normally
storing lipids and hepatocytes are not. In metabolic disease
states, such as the metabolic syndrome, it is easy to conceive
howdysregulationofautophagycouldultimatelyleadtofatty
liver with increased TG storage in the liver and decreased
storage in AT.
4. Autophagy andERStress
AutophagyandERstresspathwaysarenotdisconnectedfrom
one another as previously assumed. In contrast, activation
of both can aid in cell survival at times of stress. For
one example, autophagy oﬀers an alternative pathway for
degradation of proteins when ER-activated proteasomes can
no longer handle the load [54–58]. In addition, activation of
cell death of each pathway may be interlinked. While classic
knowledgeisbasedonERstressactivatingapoptosis through
CHOP upregulation and autophagy-mediated cell death via
a completely separate process, recent ﬁndings demonstrate
that these two cell death pathways are interlinked.
In more noxious circumstances, it has been shown that
cell death through prolonged UPR activation can occur
throughautophagy-inducedcelldeath[55].Likewise,inhibi-
tion of autophagy increases cell viability with prolonged ER
stress [59–61]. However, in nutrient overload and metabolic
disorders, impaired autophagy can increase ER stress [62],
perhaps due to decreased aberrant protein degradation and
energy turnover needed to maintain ER homeostasis. This
complex crosstalk of ER stress with the autophagy pathway is
not yet well understood. Recently, it was found that ER stress
activation can inhibit Akt phosphorylation, the upstream
inducer of autophagy at times of perceived starvation [63].
However, the responsible protein(s) are still not known and
may even be cell-type speciﬁc [64].
Another link is hypothesized to occur through the PERK
pathway of the UPR [65, 66]. Some studies have shown that
PERK phosphorylation of eIF2α leads to an upregulation of
LC3 [58]. Yet, it has not been shown if this is directly from
eIF2α phosphorylation inducing LC3 translation, or through
ATF-4 activation increasing Atg12 transcription [67, 68]. In
fact, our current studies suggest that HIV Protease inhibitor
(PI)-induced activation of autophagy is closely linked to ER
stress via the ATF-4 pathway. We have found that those HIV
PIs that induce metabolic side eﬀects in the clinic also induce
ER stress and autophagy in hepatocytes and adipocytes. The
correspondingactivationofautophagyseemstobeoneofthe
underlying factors by which HIV PIs induce dysregulation of
lipid metabolism.
Recent studies have shown a strong link between ac-
tivation of ER stress, increased autophagy induction, and
increased SREBP activity leading to lipid overload in hep-
atocytes [69], although a mechanism remains to be deter-
mined. One group of investigators has demonstrated the
capability of SREBP-2 to directly upregulate the expression
of autophagy essential proteins [70], giving signiﬁcance
to a previous ﬁnding that cholesterol depletion leads to
autophagy induction in multiple cell lines [71]. Additionally,
knockdown of SREBP-2 decreased LC3 association with LDs
in hepatocytes [70]. Although SREBPs are not a current
forefront of proposed activators of autophagy, it is probable
that in times of cellular lipid depletion, LDs are processed for
moreessentialcellularrequirements,andthispathwaycanbe
activated through ER stress-induced activation of SREBPs.
Although these investigations have not been completed in
adipocytes, our laboratory has found that in addition to
HIV PIs inducing ER-stress and autophagy in adipocytes,Biochemistry Research International 5
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Figure 1: Potential link between ER stress signaling pathways and
lipid droplet formation in adipocytes.
SREBP-1cactivationisalsoaltered.Untilmoreinvestigations
are completed, the exact stream can only be hypothesized
(Figure 1).
5. ER Stress andInﬂammation
Obesity and resulting metabolic diseases such as insulin
resistance are now known to be strongly associated with
chronic inﬂammation, a substantial risk factor for fur-
ther complications, most notably atherosclerosis. Increased
plasma concentrations of IL-6 and TNF-α have been repeat-
edly noted in obese individuals [72–74]. Investigations into
mechanisms underlying obesity and diabetes has demon-
strated that inﬂammation in AT can detrimentally alter
human physiology.
With increasing overload, adipocytes begin to hypertro-
phy. Cells become stressed from the actual expansion and
from exceeding an adequate oxygen diﬀusion distance in
tissue [75, 76]. Adipocytes then signal with a release of
proinﬂammatory IL-6 and TNF-α cytokines, which activate
resident macrophages as well as induce inﬁltration of cir-
culating macrophages. Stressed adipocytes are subsequently
engulfed, resulting in the formation of characteristic crown-
like structures.
During this process, released IL-6 and TNF-α from
stressed adipocytes and activated macrophages can inhibit
adipogenesis [77]. In fact, TNF-α alone is enough to inhibit
induction of PPARγ and C/EBPα [78]. Even more, the
induction of inﬂammation can also lead to insulin resistance
inAT,alreadywellknownandcontinuouslyinvestigated[79–
82]. Taken together, the ability to store excess energy in AT is
drastically decreased with the decrease of mature adipocytes
and the death of cells.
Even more, ER stress has been shown to be activated
at times of overnutrition [8]. In adipocytes, ER stress can
be activated due to the need of LD synthesis, enzyme pro-
duction, and conversion of energy to TG at times of over-
nutrition. Importantly, ER stress has repeatedly been shown
to induce the cellular inﬂammatory cascade through the
c-Jun N-terminal kinase (JNK) pathway, and JNK has
been shown to be upregulated in AT of obese individuals
[83, 84]. Additionally, ER stress may trigger the adipocyte
inﬂammatory cascade through PERK activating IKB kinase
β (IKKβ) when cells are stimulated with free fatty acids
[85]. This pathway is also known to be a heavy regulator
of inﬂammatory cytokine release and, together with JNK
activation, would lead to the proinﬂammatory state seen in
AT in metabolic disease states.
Proinﬂammatory proﬁle at times of overnutrition is not
unique to AT, but occurs throughout the body. However,
AT is unique in that it is solely responsible for the sub-
sequent decrease of adiponectin secretion. Adiponectin is
an adipocyte-speciﬁc anti-inﬂammatory cytokine that neg-
atively correlates with cardiovascular disease and fatty liver
disease[86–88],withadecreaseofsecretioninoverexpanded
or stressed tissue [89]. It has been found that adiponectin
can alleviate ER stress [90]. Zhou et al. have shown that ER
stress initiation is suﬃcient to decrease adiponectin release.
In animal models, they demonstrated that stabilization of
adiponectin protein can decrease obesity-induced ER stress
in AT [90]. In vitro, induction of autophagy could alleviate
ER stress responses and subsequently stabilize adiponectin
secretions [91]. These are promising ﬁndings, and more
studies are needed to determine if upregulation of autophagy
could ultimately lead to therapeutic options for metabolic
diseases (Figure 2).
6. FutureDirections
We have provided ample references demonstrating that ER
stress can induce lipid metabolism dysregulation in adipo-
cytes. Such an assertion is not only important for interested
molecular biologists, but for clinicians as well. It has been
shown that fat depots of obese patients have increased ER
stress [84, 92, 93]. What is more, there may be a link between
ER stress upregulation, the inﬂammatory state of this tissue,
and insulin resistance [84, 92, 94, 95].
The cycle of overnutrition, ER stress, and AT pathology
is complex. With the information provided here and our
own ﬁndings, we support the hypothesis that inhibiting ER
stress activation may be therapeutically beneﬁcial in the
treatment of metabolic diseases. Chaperones, which enhance
ER-protein-folding capacity, have shown potential in the
laboratory.
TwochaperonesalreadyFDAapprovedhavebeenstudied
in hepatocytes, adipocytes, and β-cells for their ability to
relieve ER-stress-induced dysfunctions, namely, 4-phenyl-
butyric acid (PBA) and taurine-conjugated ursodeoxycholic
acid (TUDCA). Both were shown to relieve insulin resistance
in adipocytes at times of ER stress [96, 97]. In addition, they
were able to decrease JNK and IKKβ activity when cells were
stimulated with ER stress inducers, including free fatty acids
[85, 96]. In vivo, PBA and TUDCA were able to relieve ER
stress activation in obese mice [96]. However, further studies
are needed to conﬁrm these beneﬁcial eﬀects and elaborate
on the extent that chaperone treatment may aid in nutrition
overload-induced ER stress and downstream alterations.6 Biochemistry Research International
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Figure 2: ER-stress-induced inﬂammation in adipocytes and macrophages contributes to atherosclerosis and fatty liver diseases.
Inhibiting ER stress activation may be the key to an
approach for metabolic syndrome therapy. However, more
questions remain in this ﬁeld. Namely, the role of all parts
of the UPR in adipocyte lipid metabolism needs to be
uncovered, and the mechanism intertwining ER stress and
autophagy needs to be further elucidated. Understanding
these missing components will allow not only further un-
derstanding of key lipid pathways in a central metabolic cell
type, but also help determine the best approach that can be
utilized for clinical metabolic dysfunctions in patients with
altered AT physiology.
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